ABSTRACT BACKGROUND/OBJECTIVES The hemoglobin glycation index (HGI) has been demonstrated to serve as a substitute for the individual bias in glycosylated hemoglobin A1c (HbA1c). Our

objective was to assess the correlation between HGI and cardiovascular (CV) outcomes in patients with diabetes and coronary artery disease (CAD). SUBJECTS/METHODS We sequentially recruited

11921 patients with diabetes and CAD at Fuwai Hospital. The patients were categorized into five groups based on their HGI quintiles, ranging from Q1 to Q5. The primary endpoint was the

occurrence of major adverse cardiac events (MACEs), which included CV death and nonfatal myocardial infarction. RESULTS During the median 3-year follow-up, 327 (2.7%) MACEs were observed. A

HGI were linked to a higher risk of MACEs (all _P_ < 0.05). Patients with a low HGI (Q1) had a significantly increased risk of all-cause and CV death, with a 1.70-fold increase in both

cases (both _P_ < 0.05). CONCLUSIONS In individuals with diabetes and established CAD, HGI levels were found to have a U-shaped relationship with the occurrence of MACEs over a period of

three years. Significantly, those with low HGI had an increased risk of CV death. SIMILAR CONTENT BEING VIEWED BY OTHERS U-SHAPED ASSOCIATION BETWEEN HBA1C AND ALL-CAUSE MORTALITY IN CVD

PATIENTS WITH DIABETES Article Open access 18 November 2024 CLINICAL IMPLICATIONS AND PHARMACOLOGICAL CONSIDERATIONS OF GLYCEMIC VARIABILITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Article

Open access 14 October 2024 GLYCATED HAEMOGLOBIN INDEX IS A NEW PREDICTOR FOR ALL-CAUSE MORTALITY AND CARDIOVASCULAR MORTALITY IN THE ADULTS Article Open access 23 August 2024 INTRODUCTION

Globally, cardiovascular (CV) disease, particularly coronary artery disease (CAD), continues to be the primary cause of death [1]. Diabetes is well recognized as a significant contributor

and risk factor for CAD [2]. For patients with diabetes and CAD, it is crucial to effectively control blood sugar levels and use reliable indicators, such as glycosylated hemoglobin A1c

(HbA1c) to minimize diabetes-related complications and mortality [3]. While HbA1c assays have been standardized, discrepancies between HbA1c and other glycemic assessments have been observed

and might affect the accurate interpretation and treatment of glycemic control [4, 5]. Glucose gradient across the red blood cell membrane and red blood cell turnover may affect the HbA1c

level independently of glycemia [6]. Therefore, HbA1c levels may deviate from blood sugar levels in a consistent manner owing to several variables that affect the process of glycation inside

red blood cells, resulting in HbA1c values that are either lower or higher than anticipated. To solve these problems, Hempe et al. [7] developed the hemoglobin glycation index (HGI) as a

means to assess the variation in individual HbA1c levels. HGI was determined by subtracting the projected HbA1c, based on blood glucose estimates using linear regression, from the observed

HbA1c [8]. Presently, there have been few research that examined the correlation between CV outcomes and HGI, and the findings have been rather contentious. Prior research has shown that

patients with elevated HGI are more susceptible to developing diabetes-related retinopathy [9], nephropathy [10], and CV complications for patients with diabetes [8]. However, recent studies

with limited sample sizes have shown that people with diabetes who have low HGI are more likely to have CV events compared to those with intermediate HGI [11, 12]. Currently, there has been

no research conducted to examine the impact of HGI on CV outcomes in individuals who have diabetes and established CAD. Our objective was to examine the correlation between the HGI and the

prognosis in individuals diagnosed with both diabetes and CAD. MATERIALS/SUBJECTS AND METHODS STUDY DESIGN AND POPULATION This study was a retrospective analysis of a prospective cohort done

at Fuwai Hospital, Chinese Academy of Medical Sciences. The study was approved by the Institutional Review Board of Fuwai Hospital and followed the guidelines set forth in the Declaration

of Helsinki. All participants provided written informed consent. This research was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology

(STROBE) reporting criteria [13]. Between January 2017 and December 2018, a total of 13,506 individuals diagnosed with diabetes and angiography-confirmed CAD had regular post-discharge

monitoring. Inclusion criteria were: 1) age ≥ 18 years; 2) participants had to have angiography results confirming the presence of CAD, with at least one coronary artery showing a stenosis

of 50% or more; 3) participants had to have a confirmed diagnosis of diabetes. Diabetes was diagnosed if the patient had a previous diagnosis of diabetes, was on treatment to decrease

glucose levels, or had a fasting blood glucose (FBG) level of 7.0 mmol/L or higher, HbA1c level of 6.5% or higher, or a 2-hour plasma glucose level of 11.1 mmol/L or higher during an oral

glucose tolerance test [3]. Exclusion criteria were: 1) absence of important laboratory data; 2) severe liver or renal malfunction; 3) decompensated heart failure; 4) systemic inflammatory

illness; 5) malignant tumor; 6) anemia; 7) hematological disorder; and 8) patient who lost to follow-up. Finally, 11921 individuals diagnosed with both diabetes and CAD were included in this

study (Fig. S1). DERIVING HGI FROM THE HBA1C VERSUS FBG REGRESSION EQUATION The calculation of HGI was performed using the methods proposed by Hempe et al. [8]. Briefly, the baseline FBG

and HbA1c data of all individuals were used to assess the linear relationship between FBG and HbA1c in the study group. (Fig. S2). Subsequently, a predicted HbA1c value was calculated by

combining the baseline FBG with the subsample linear regression equation (predicted HbA1c = 0.013 × FBG [mmol/L] + 5.455). The baseline HGI was calculated by subtracting the expected HbA1c

from the actual HbA1c. All participants would be classified based on their baseline HGI quintiles (quintile 1 [Q1]: ≤ −0.840; Q2: −0.840 to −0.322; Q3: −0.322 to 0.075; Q4: 0.075 to 0.790;

Q5: ≥ 0.790). DATA COLLECTION AND DEFINITIONS Demographic and clinical information for all patients was obtained prospectively. The demographic data collected consisted of age, sex, body

mass index (BMI), presence of concomitant disorders, smoking status, family history of CAD, history of prior myocardial infarction (MI), and history of percutaneous coronary intervention

(PCI) or coronary artery bypass grafting (CABG). The clinical data included the primary diagnosis at admission, the results of physical, radiological, and laboratory examinations, and the

prescribed drug regimen upon discharge. Upon admission, we obtained laboratory samples from each participant by drawing blood from the cubital vein after a minimum of 12 h of fasting. Our

center’s clinical chemistry branch conducted all the exams. An enzymatic test was used to assess the amounts of triglycerides (TG), total cholesterol (TC), high-density lipoprotein

cholesterol (HDL-C), FBG, and creatinine. The analysis was performed using an automated biochemical analyzer (Hitachi 7150, Tokyo, Japan). The calculation of low-density lipoprotein

cholesterol (LDL-C) was performed using the Friedewald technique [14]. HbA1c was determined using high-performance liquid chromatography (Tosoh G8 HPLC Analyzer; Tosoh Bioscience, Tokyo,

Japan). The high sensitivity C reactive protein (hsCRP) was analyzed using conventional biochemical methods at the central laboratory of Fuwai Hospital. The estimated glomerular filtration

rate (eGFR) was determined using the Chinese-modified Modification of Diet in Renal Disease equation [15]. The modified biplane Simpson rule was used to evaluate the left ventricular

ejection fraction (LVEF) at a state of rest [16]. The procedure of coronary angiography was carried out using standard techniques by experienced interventional cardiologists. Two experienced

interventional cardiologists, working separately, examined the angiographic data obtained from the catheter laboratory at Fuwai Hospital. They documented the specific features of CAD,

including unique types of narrowing in the coronary arteries, as well as the SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) score. Hypertension

was characterized as having a systolic blood pressure (SBP) equal to or more than 140 mmHg, a diastolic blood pressure (DBP) equal to or greater than 90 mmHg, or the use of antihypertensive

treatment [17]. Chronic kidney disease (CKD) was defined as the eGFR < 60 mL/min/1.73 m2 persisting for a duration of at least 3 months [18]. FOLLOW‐UP AND STUDY ENDPOINTS Participants

were monitored at 6-month intervals until December 31, 2021, after their discharge. The data for endpoints were collected from medical records, clinical visits, and/or telephone interviews

by experienced investigators who were unaware of the study design. The primary endpoint was the major adverse cardiac event (MACE), which included CV death and nonfatal myocardial infarction

(MI). The secondary endpoints included all-cause death, CV death, nonfatal MI, and unplanned revascularization. Death was classified as CV-related unless a clear non-CV cause could be

determined. Nonfatal MI was defined as the presence of positive cardiac troponins together with typical chest pain, characteristic electrocardiogram serial alterations, identification of an

intracoronary thrombus by angiography or autopsy, or imaging data indicating fresh loss of viable myocardium or a new regional wall-motion abnormality [19]. Unplanned revascularization

refers to the need for a treatment to restore blood flow to a lesion that did not satisfy the threshold for ischemia during the first operation and was not intended to be treated with a

subsequent planned revascularization. Two separate physicians meticulously assessed all events. STATISTICAL ANALYSIS Continuous variables were presented as mean ± standard deviation (SD) or

median (interquartile range, IQR), and were compared using either the Student t-test or the Mann-Whitney U test. Categorical variables were represented as numerical values and percentages,

and were compared using either the Fisher’s exact test or the chi-square test. The Kaplan-Meier curves were used to demonstrate the cumulative incidence of clinical endpoints across

different groups, and the log-rank test was then used to compare these incidences. After adjusting for age and sex, we used restricted cubic spline (RCS) models to examine the presence of

nonlinearity between continuous HGI and the likelihood of experiencing MACE during a 3-year period. The hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using both

univariable and multivariable Cox regression models. The multivariable Cox regression model used age, sex, BMI, duration of diabetes, acute coronary syndrome (ACS) presentation, family

history of CAD, MI histories, previous revascularization, hypertension, previous stroke, PAD, current smoker, LVEF, serum creatinine, TG, LDL-C, HDL-C, TC, hsCRP, LM/three-vessel disease,

chronic total occlusion (CTO) lesion, ostial lesion, type B2/C lesion, severe calcification, aspirin use, statins use, and insulin use as covariates. A two-tailed P value less than 0.05 was

considered to be statistically significant. The analyses were performed using R version 4.0.3 software (R Foundation, Vienna, Austria). RESULTS BASELINE CHARACTERISTICS ACCORDING TO HGI

QUINTILES A total of 11921 patients were ultimately included. The mean age was 60.69 ± 9.78 years, and 8955 (75.1%) were male. Additionally, 9014 (75.6%) patients had hypertension, and 3639

(30.5%) were currently smoking (Table 1). The participants were divided into five groups based on their HGI quintiles: Q1 (_N_ = 2384), Q2 (_N_ = 2375), Q3 (_N_ = 2389), Q4 (_N_ = 2387), and

Q5 (_N_ = 2386). The detailed baseline data for each group can be found in Table 2. In general, individuals with a low HGI (Q1) had a higher likelihood of being diagnosed with ACS and

having a history of MI, CKD, poorer LVEF, higher serum creatinine levels, and higher SYNTAX scores. These patients also had more thrombotic lesions, ostial lesions, and type B2/C lesions.

Patients with high HGI (Q5) exhibited elevated levels of HbA1c, FBG, TC, LDL-C, and were prescribed more glucose-lowering medications. The Spearman correlation analysis revealed a high

positive association between the HGI and HbA1c values (β = 0.845, _P_ < 0.001). In addition, the HGI exhibited a positive correlation with conventional CV risk variables, including BMI,

duration of diabetes, LVEF, SBP, TC, LDL-C, and hsCRP, and inversely correlated with serum creatinine, eGFR, and HDL-C (Table S1). The distribution of HbA1c varied significantly across the

quantiles of HGI, although the distribution of FBG was consistent throughout the HGI quantiles (Fig. S3). HGI AND ADVERSE CV EVENTS RISK Over the course of the 3-year follow-up period, a

total of 327 MACEs were documented (Table S2). The incidence of MACEs in the HGI Q1 to Q5 groups were 79 (3.3%), 46 (1.9%), 52 (2.2%), 75 (3.1%), and 75 (3.1%) correspondingly. RCS showed a

U-shaped relationship between HGI and 3-year MACEs after multivariable adjustment (non-linear _P_ = 0.014, Fig. 1). Kaplan-Meier survival analyses revealed a statistically significant

disparity in the occurrence of MACEs among the five groups after a 3-year follow-up. Notably, the HGI Q2 group exhibited the lowest rates of MACEs (all _P_ values < 0.001, Fig. 2). The

findings of univariable and multivariable Cox regression models were displayed in Table 2. Results of the multivariable Cox regression analyses indicated that, when compared to subjects in

the HGI Q2 group, subjects in the HGI Q1 group had a higher risk of MACEs, CV death, and all-cause death at the 3-year follow-up. The adjusted HR were 1.50 (95% CI: 1.04–2.17), 1.70 (95% CI:

1.10–2.62), and 1.70 (95% CI: 1.19–2.45) for MACEs, CV death, and all-cause death, respectively. Patients categorized in the high HGI quartiles (Q4 and Q5) had a significantly greater risk

of MACEs, all-cause death, and unplanned revascularization compared to patients in the Q2 of HGI (all _P_ < 0.05). There was no noticeable disparity in the risk of any MACEs between

patients in the second and third quartiles of HGI. DISCUSSION This study examined the relationship between HGI and CV outcomes over a period of three years in patients with diabetes and

existing CAD. The major discoveries are as follows: 1) Patients with diabetes and CAD exhibit significant variations in their clinical and angiographic characteristics based on their HGI

quintiles. Those with low HGI levels have a higher prevalence of comorbid risk factors and more complex coronary lesions, leading to more acute clinical presentations. 2) RCS analysis

indicates a U-shaped relationship between HGI and 3-year MACEs. 3) Multivariable Cox regression models demonstrate that both low and high HGI levels are associated with an increased risk of

MACE or all-cause death during the 3-year follow-up period. 4) The presence of low HGI primarily contributes to elevated CV and all-cause mortality rates, while higher HGI levels are

associated with an increase in unplanned revascularization rates. 5) There is a strong correlation between HGI and HbA1c levels (β = 0.845), suggesting that including HbA1c in an analysis

alongside HGI may introduce statistical spuriousness. Our findings initially validated the potential of HGI in mitigating errors in assessing and treating blood glucose levels, which can

occur when relying solely on HbA1c and leading to underestimation or overestimation. A high HGI indicates that the HbA1c level reflects a greater blood glucose level than what is actually

present. As a result, patients with a high HGI may receive excessive hypoglycemic medication and face an increased risk of hypoglycemia. People with a low HGI have a blood glucose level, as

measured by HbA1c, that is lower than their actual blood glucose level. As a result, these persons may not receive the appropriate glucose-lowering treatment and are at a higher risk of

experiencing problems related to diabetes. The measurement of HGI is helpful for doctors and their patients as it allows for personalized clinical care and helps prevent harm that may result

from incorrect evaluation of glycemic levels and therapeutic management. Debates continue to exist regarding the influence of glycemic control on CV events for individuals with diabetes.

Although several CV outcome trials, such as VADT [20], ACCORD [21], and ADVANCE [22], have not demonstrated a significant decrease in the risk of CV events with more rigorous glycemic

control compared to standard care for diabetes, other studies like DCCT/EDIC [23] and UKPDS [24] have suggested a potential advantage of strict glycemic management in reducing the occurrence

of CV events. Identifying patients who would benefit the most from glycemic management could offer useful understanding of this matter, and various innovative biomarkers have been created

to assist in guiding glycemic management for individuals with diabetes [25]. An example of such a biomarker is the triglyceride-glucose (TyG) index, which has been acknowledged for its

ability to predict the occurrence and prognosis of individuals with diabetes and CAD [25]. A recent study has discovered a more pronounced connection between glycemic control status and

adverse CV events in persons with elevated TyG levels. This suggests that the TyG index could be helpful in assessing the risk of patients with diabetes and CAD [25]. Our study revealed that

HGI can serve as a valuable biomarker in preventing errors resulting from relying solely on HbA1c to assess blood glucose levels in individuals with diabetes and CAD from a different

standpoint. HGI might help to avoid underestimation or overestimation of blood glucose levels during glycemic treatment. The prevailing methods for glycemia management in individuals with

diabetes primarily rely on HbA1c [26, 27]. Although assays of HbA1c have been standardized, there are still differences between HbA1c and other glycemic measurements that have been

extensively established. These differences have the potential to affect how glycemic control is interpreted and treated [4, 5, 28]. The HbA1c measurement is affected by various factors

related to the lifespan and turnover of red blood cells, as well as the glucose concentration across the red blood cell membrane, regardless of blood sugar levels [29, 30]. In order to

address these issues, the HGI was created to quantify the discrepancy between HbA1c levels and blood glucose measurements [31, 32]. It is worth mentioning that HGI remains constant in

individuals over time. Hempe et al. [7] collected blood glucose data from 128 patients with type 1 diabetes over a period of two years. During the study period, it was observed that HbA1c

and blood glucose levels consistently exhibited the same pattern and degree of high glycemic index (HGI), suggesting a consistent fluctuation in intracellular glycation compared to

extracellular glycation or blood glucose levels. Prior research has predominantly shown that elevated levels of HGI are linked to unfavorable prognosis and increased CV risk in individuals

with diabetes [32,33,34]. According to Van Steen et al. [33], there is a positive correlation between high HGI and increased occurrence of microvascular and macrovascular problems, as well

as death, in individuals with diabetes. Rajendran et al. [34] found that the association between lipid profile (TC, TG, and LDL-C) and HGI is not influenced by FBG levels in the extra

vascular compartment. Our research revealed that there is a direct relationship between HGI and lipid profiles related to CV disease in patients with diabetes and established CAD. This

indicates that patients with high HGI are at a greater risk of developing CV complications. However, recent studies that have employed a more detailed categorization of HGI levels have

indicated that the linear association may not truly represent the connection between HGI and CV outcomes [11, 12]. Wang et al. [12] discovered a U-shaped relationship between the levels of

HGI and the risk of MACE in patients with diabetes. They observed that both the lowest (Q1) and highest (Q5) HGI levels are associated with a greater risk of MACE compared to the middle (Q2)

group. Pan et al. [11] discovered a U-shaped correlation between the HGI and the likelihood of experiencing a stroke within 12 months. This indicates that both low and high HGIs were linked

to adverse CV outcomes. Consistent with other research, we observed that HGI levels exhibited a U-shaped correlation with the incidence of MACE during a three-year period in individuals who

have both diabetes and established CAD. The risk of death, particularly CV death, considerably rose when levels of HGI decreased. A low HGI score suggests that there is less glycation than

what was initially expected. HGI is intended to measure the difference between the actual and expected values of glycated HbA1c. The results of the ACCORD study indicated that intensive

therapy was associated with a decreased likelihood of adverse CV events in the low HGI subgroups (HR = 0.75; 95% CI: 0.59–0.95), but not in the high HGI subgroup (HR = 1.14; 95% CI:

0.93–1.40) [21]. In addition, our research revealed that individuals with low HGI had a greater prevalence of CKD and elevated blood creatinine levels. This suggests a potential correlation

between low HGI and an increased occurrence of diabetic macrovascular complications. Thus, additional future research is necessary to examine whether patients with low HGI values can derive

advantages from intensive glycemic management. Notably, our study revealed a higher occurrence of complex coronary lesions, such as thrombotic lesions and ostial lesions, among the groups

with lower HGI values and higher SYNTAX scores. Conversely, individuals with low HGI levels exhibited a higher frequency of ACS presentations accompanied by a deterioration in cardiac

function. Prior data has indicated that those with more unfavorable CV risk profiles and a higher degree of complexity in CAD are at an elevated risk of experiencing CV events [35]. Further

investigations are needed to explore the particular mechanisms linking HGI levels and lesion severity. This study, which has the largest sample size up to now, initially validated the

U-shaped correlation between HGI values and adverse CV outcomes in individuals with diabetes and existing CAD. Furthermore, we have included patients with angiography-proven CAD for the

first time. Our study reveals that the angiographic profile differs significantly among different HGI quintiles. Specifically, individuals with low HGI values exhibit a higher complexity of

coronary lesions and more acute clinical presentations. Furthermore, we observed that individuals with diabetes and CAD who had low HGI values experienced a greater likelihood of all-cause

and CV death. Nevertheless, this study has several limitations. Firstly, because of the inherent characteristics of the single center and observational study design, it is possible that

potential confounding factors may not be completely eliminated. Secondly, we employed FBG as a means of determining HGI, rather than relying on average plasma glucose measurements.

Nevertheless, FBG is more readily obtainable in practical scenarios when compared to average plasma glucose. Previous research has demonstrated a noteworthy association between FBG and

average plasma glucose levels [34]. Meanwhile, research has demonstrated that the use of FBG to compute HGI is more effective in accurately reflecting the changes in HbA1c levels [34].

Finally, given the linear association between the HGI and HbA1c level, it is impossible to exclude the potential correlation between the effects of the HGI and the HbA1c level. While the HGI

is a reliable measure, it is subject to periodic fluctuations. Determining the ideal timing for HGI testing is important. In conclusion, this large cohort study first confirmed a U-shaped

relationship between HGI and the occurrence of MACE within a three-year period in patients with diabetes and established CAD. Both low and high HGI were found to be linked to a greater risk

of MACE at the 3-year follow-up. Additionally, patients with low HGI had a higher chance of CV death. These findings imply that HGI could be useful in assessing the risk and prognosis of

this particular population. DATA AVAILABILITY Data underlying this article and the associated analysis code will be shared upon reasonable request and in accordance with the appropriate

general data protection regulation (GDPR). REFERENCES * Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From

the American Heart Association. Circulation. 2023;147:e93–e621. Article  PubMed  Google Scholar  * ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10.

Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46:S158–S90. Article  CAS  PubMed  Google Scholar  * ElSayed NA, Aleppo G, Aroda VR,

Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46:S19–S40. Article  CAS  PubMed  Google Scholar

  * Campbell L, Pepper T, Shipman K. HbA1c: a review of non-glycaemic variables. J Clin Pathol. 2019;72:12–9. Article  CAS  PubMed  Google Scholar  * Sodi R, McKay K, Dampetla S, Pappachan

JM. Monitoring glycaemic control in patients with diabetes mellitus. BMJ. 2018;363:k4723. Article  PubMed  Google Scholar  * Nayak AU, Singh BM, Dunmore SJ. Potential Clinical Error Arising

From Use of HbA1c in Diabetes: Effects of the Glycation Gap. Endocr Rev. 2019;40:988–99. Article  PubMed  Google Scholar  * Hempe JM, Gomez R, McCarter RJ Jr, Chalew SA. High and low

hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications. 2002;16:313–20. Article  PubMed  Google Scholar  * Hempe JM,

Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care.

2015;38:1067–74. Article  CAS  PubMed  PubMed Central  Google Scholar  * McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and

nephropathy in type 1 diabetes. Diabetes Care. 2004;27:1259–64. Article  CAS  PubMed  Google Scholar  * Kim W, Go T, Kang DR, Lee EJ, Huh JH. Hemoglobin glycation index is associated with

incident chronic kidney disease in subjects with impaired glucose metabolism: A 10-year longitudinal cohort study. J Diabetes Complications. 2021;35:107760. Article  CAS  PubMed  Google

Scholar  * Pan Y, Jing J, Wang Y, Liu L, Wang Y, He Y. Association of hemoglobin glycation index with outcomes of acute ischemic stroke in type 2 diabetic patients. Neurol Res.

2018;40:573–80. Article  PubMed  Google Scholar  * Wang Y, Liu H, Hu X, Wang A, Wang A, Kang S, et al. Association between hemoglobin glycation index and 5-year major adverse cardiovascular

events: the REACTION cohort study. Chin Med J (Engl). 2023;136:2468–75. Article  CAS  PubMed  Google Scholar  * von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et

al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7. Article  Google

Scholar  * Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin

Chem. 1972;18:499–502. Article  CAS  PubMed  Google Scholar  * Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients

with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937–44. Article  PubMed  Google Scholar  * Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al.

Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of

Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–67. Article  CAS  PubMed  Google Scholar  * Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.

2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104. Article  PubMed  Google Scholar  * Stevens PE, Levin A, Kidney Disease: Improving Global

Outcomes Chronic Kidney Disease Guideline Development Work Group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012

clinical practice guideline. Ann Intern Med. 2013;158:825–30. Article  PubMed  Google Scholar  * Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal

definition of myocardial infarction. Eur Heart J. 2012;33:2551–67. Article  PubMed  Google Scholar  * Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control

and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39. Article  CAS  PubMed  Google Scholar  * Action to Control Cardiovascular Risk in Diabetes Study G,

Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. Article  Google Scholar  * Group

AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72. Article

  Google Scholar  * Diabetes C. Complications Trial /Epidemiology of Diabetes I, Complications Study Research G. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes:

The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016;39:686–93. Article  Google Scholar  * Effect of intensive blood-glucose control with metformin on complications in overweight

patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854–65. * Lin Z, He J, Yuan S, Song C, Bian X, Yang M, et al. Glycemic control and

cardiovascular outcomes in patients with diabetes and coronary artery disease according to triglyceride-glucose index: a large-scale cohort study. Cardiovasc Diabetol. 2024;23:11. Article 

CAS  PubMed  PubMed Central  Google Scholar  * ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes

Care. 2023;46:S97–S110. Article  PubMed  Google Scholar  * Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, Group Ac-DAGS. Translating the A1C assay into estimated average

glucose values. Diabetes Care. 2008;31:1473–8. Article  CAS  PubMed  PubMed Central  Google Scholar  * Nayak AU, Holland MR, Macdonald DR, Nevill A, Singh BM. Evidence for consistency of the

glycation gap in diabetes. Diabetes Care. 2011;34:1712–6. Article  PubMed  PubMed Central  Google Scholar  * Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, et al.

Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes. 2008;57:2445–52. Article 

CAS  PubMed  PubMed Central  Google Scholar  * Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, et al. Red cell life span heterogeneity in hematologically normal people is

sufficient to alter HbA1c. Blood. 2008;112:4284–91. Article  CAS  PubMed  PubMed Central  Google Scholar  * Rodriguez-Segade S, Rodriguez J, Garcia Lopez JM, Casanueva FF, Camina F.

Estimation of the glycation gap in diabetic patients with stable glycemic control. Diabetes Care. 2012;35:2447–50. Article  PubMed  PubMed Central  Google Scholar  * Ahn CH, Min SH, Lee DH,

Oh TJ, Kim KM, Moon JH, et al. Hemoglobin Glycation Index Is Associated With Cardiovascular Diseases in People With Impaired Glucose Metabolism. J Clin Endocrinol Metab. 2017;102:2905–13.

Article  PubMed  PubMed Central  Google Scholar  * van Steen SC, Woodward M, Chalmers J, Li Q, Marre M, Cooper ME, et al. Haemoglobin glycation index and risk for diabetes-related

complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2018;61:780–9. Article  PubMed 

PubMed Central  Google Scholar  * Rajendran S, Mishra S, Madhavanpillai M, Vishnupriya G. Association of hemoglobin glycation index with cardiovascular risk factors in non-diabetic adults: A

cross-sectional study. Diabetes Metab Syndr. 2022;16:102592. Article  CAS  PubMed  Google Scholar  * Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021

ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation. 2022;145:e4–e17. PubMed  Google Scholar  Download references FUNDING Funding This work was supported by CAMS Innovation Fund for Medical Sciences (CIFMS) (grant no.

2021-I2M-1-008). AUTHOR INFORMATION Author notes * These authors contributed equally: Zhangyu Lin, Jining He. AUTHORS AND AFFILIATIONS * State Key Laboratory of Cardiovascular Disease,

Beijing, China Zhangyu Lin, Jining He, Sheng Yuan, Chenxi Song, Xiaohui Bian & Kefei Dou * Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases,

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Zhangyu Lin, Jining He, Sheng Yuan, Chenxi Song, Xiaohui Bian & Kefei Dou * Department of Cardiology,

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Zhangyu Lin, Jining He, Sheng Yuan, Chenxi

Song, Xiaohui Bian, Min Yang & Kefei Dou * National Clinical Research Center for Cardiovascular Diseases, Beijing, China Kefei Dou Authors * Zhangyu Lin View author publications You can

also search for this author inPubMed Google Scholar * Jining He View author publications You can also search for this author inPubMed Google Scholar * Sheng Yuan View author publications You

can also search for this author inPubMed Google Scholar * Chenxi Song View author publications You can also search for this author inPubMed Google Scholar * Xiaohui Bian View author

publications You can also search for this author inPubMed Google Scholar * Min Yang View author publications You can also search for this author inPubMed Google Scholar * Kefei Dou View

author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS Zhangyu Lin: Conceptualization, Investigation, Methodology, Formal analysis, Visualization,

Writing – original draft. Jining He: Methodology, Software, Visualization, Writing – original draft. Sheng Yuan: Methodology. Chenxi Song: Methodology. Xiaohui Bian: Methodology. Min Yang:

Supervision, Validation. Kefei Dou: Conceptualization, Supervision, Validation, Data curation, Writing – review & editing. CORRESPONDING AUTHORS Correspondence to Min Yang or Kefei Dou.

ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ETHICS This study was approved by the Institutional Review Board of Fuwai Hospital and complied with the

Declaration of Helsinki. Written informed consent was obtained from all subjects. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims

in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMENTARY MATERIALS RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons

Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original

author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the

article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use

is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Lin, Z., He, J., Yuan, S. _et al._ Hemoglobin glycation index and cardiovascular

outcomes in patients with diabetes and coronary artery disease: insights from a large cohort study. _Nutr. Diabetes_ 14, 69 (2024). https://doi.org/10.1038/s41387-024-00318-x Download

citation * Received: 03 March 2024 * Revised: 11 July 2024 * Accepted: 16 July 2024 * Published: 28 August 2024 * DOI: https://doi.org/10.1038/s41387-024-00318-x SHARE THIS ARTICLE Anyone

you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative